Commentary: Pharmaceutical Companies More Careful About Off-Label Promotion

Merrill Goozner, the author of the author of The $800 Million Pill: The Truth Behind the Cost of New Drugs, questions the assumption that a greater push toward compliance has reduced off-label drug promotion in an editorial in MassDevice.

Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn't mean they aren't still promoting the drugs.

Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers